Shots:

• The P-III study (GLOW) evaluating Imbruvica + venetoclax (I+V) vs chlorambucil + obinutuzumab (Clb+O) in a ratio (1:1) in 211 patients aged ≥65yrs. with CLL/SLL
• The results showed a 79% reduction in risk of progression or death with a median follow-up of 46mos. & OS benefits were observed, 74.6% vs 24.8% were alive & progression-free before untreated older & comorbid @3.5yrs.; PFS was higher for uIGHV & mIGHV CLL & was sustained regardless of MRD status @3mos. along with robust efficacy with a superior & sustained PFS benefit
• ≥90% estimated PFS for mIGHV CLL, independent of MRD status & 60% with uIGHV CLL who achieved undetectable MRD. The safety profile was consistent with known safety profiles of I+V

Ref: Janssen | Image: Janssen